These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37845827)

  • 1. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol.
    Davies C; Bossong MG; Martins D; Wilson R; Appiah-Kusi E; Blest-Hopley G; Zelaya F; Allen P; Brammer M; Perez J; McGuire P; Bhattacharyya S
    Psychol Med; 2024 Apr; 54(5):993-1003. PubMed ID: 37845827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk.
    Davies C; Bossong MG; Martins D; Wilson R; Appiah-Kusi E; Blest-Hopley G; Allen P; Zelaya F; Lythgoe DJ; Brammer M; Perez J; McGuire P; Bhattacharyya S
    Schizophr Bull Open; 2023 Jan; 4(1):sgad022. PubMed ID: 39145348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.
    Bhattacharyya S; Wilson R; Appiah-Kusi E; O'Neill A; Brammer M; Perez J; Murray R; Allen P; Bossong MG; McGuire P
    JAMA Psychiatry; 2018 Nov; 75(11):1107-1117. PubMed ID: 30167644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of diazepam on hippocampal blood flow in people at clinical high risk for psychosis.
    Livingston NR; Kiemes A; Devenyi GA; Knight S; Lukow PB; Jelen LA; Reilly T; Dima A; Nettis MA; Casetta C; Agyekum T; Zelaya F; Spencer T; De Micheli A; Fusar-Poli P; Grace AA; Williams SCR; McGuire P; Egerton A; Chakravarty MM; Modinos G
    Neuropsychopharmacology; 2024 Aug; 49(9):1448-1458. PubMed ID: 38658738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis.
    Davies C; Wilson R; Appiah-Kusi E; Blest-Hopley G; Brammer M; Perez J; Murray RM; Allen P; Bossong MG; McGuire P; Bhattacharyya S
    Transl Psychiatry; 2020 Sep; 10(1):311. PubMed ID: 32921794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.
    Modinos G; Richter A; Egerton A; Bonoldi I; Azis M; Antoniades M; Bossong M; Crossley N; Perez J; Stone JM; Veronese M; Zelaya F; Grace AA; Howes OD; Allen P; McGuire P
    Neuropsychopharmacology; 2021 Jul; 46(8):1468-1474. PubMed ID: 33941857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.
    Appiah-Kusi E; Petros N; Wilson R; Colizzi M; Bossong MG; Valmaggia L; Mondelli V; McGuire P; Bhattacharyya S
    Psychopharmacology (Berl); 2020 Apr; 237(4):1121-1130. PubMed ID: 31915861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
    O'Neill A; Wilson R; Blest-Hopley G; Annibale L; Colizzi M; Brammer M; Giampietro V; Bhattacharyya S
    Psychol Med; 2021 Mar; 51(4):596-606. PubMed ID: 31994476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Striatal and Reduced Prefrontal Cerebral Blood Flow in Clinical High Risk for Psychosis.
    Kindler J; Schultze-Lutter F; Hauf M; Dierks T; Federspiel A; Walther S; Schimmelmann BG; Hubl D
    Schizophr Bull; 2018 Jan; 44(1):182-192. PubMed ID: 28575528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis.
    Gunasekera B; Wilson R; O'Neill A; Blest-Hopley G; O'Daly O; Bhattacharyya S
    Psychol Med; 2023 Jul; 53(10):4732-4741. PubMed ID: 35775365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabidiol modulation of hippocampal glutamate in early psychosis.
    O'Neill A; Annibale L; Blest-Hopley G; Wilson R; Giampietro V; Bhattacharyya S
    J Psychopharmacol; 2021 Jul; 35(7):814-822. PubMed ID: 33860709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis.
    Davies C; Paloyelis Y; Rutigliano G; Cappucciati M; De Micheli A; Ramella-Cravaro V; Provenzani U; Antoniades M; Modinos G; Oliver D; Stahl D; Murguia S; Zelaya F; Allen P; Shergill S; Morrison P; Williams S; Taylor D; McGuire P; Fusar-Poli P
    Neuropsychopharmacology; 2019 Jun; 44(7):1300-1309. PubMed ID: 30626906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome.
    Modinos G; Allen P; Zugman A; Dima D; Azis M; Samson C; Bonoldi I; Quinn B; Gifford GWG; Smart SE; Antoniades M; Bossong MG; Broome MR; Perez J; Howes OD; Stone JM; Grace AA; McGuire P
    Schizophr Bull; 2020 Apr; 46(3):670-679. PubMed ID: 32227226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cannabidiol (CBD) on regional cerebral blood flow.
    Crippa JA; Zuardi AW; Garrido GE; Wichert-Ana L; Guarnieri R; Ferrari L; Azevedo-Marques PM; Hallak JE; McGuire PK; Filho Busatto G
    Neuropsychopharmacology; 2004 Feb; 29(2):417-26. PubMed ID: 14583744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study.
    Bloomfield MAP; Green SF; Hindocha C; Yamamori Y; Yim JLL; Jones APM; Walker HR; Tokarczuk P; Statton B; Howes OD; Curran HV; Freeman TP
    J Psychopharmacol; 2020 Sep; 34(9):981-989. PubMed ID: 32762272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
    Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
    J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort.
    Allen P; Azis M; Modinos G; Bossong MG; Bonoldi I; Samson C; Quinn B; Kempton MJ; Howes OD; Stone JM; Calem M; Perez J; Bhattacharayya S; Broome MR; Grace AA; Zelaya F; McGuire P
    Schizophr Bull; 2018 Oct; 44(6):1323-1331. PubMed ID: 29294102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis.
    Allen P; Chaddock CA; Egerton A; Howes OD; Bonoldi I; Zelaya F; Bhattacharyya S; Murray R; McGuire P
    Am J Psychiatry; 2016 Apr; 173(4):392-9. PubMed ID: 26684922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report.
    Davies C; Appiah-Kusi E; Wilson R; Blest-Hopley G; Bossong MG; Valmaggia L; Brammer M; Perez J; Allen P; Murray RM; McGuire P; Bhattacharyya S
    Eur Arch Psychiatry Clin Neurosci; 2022 Apr; 272(3):461-475. PubMed ID: 34480630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis.
    Wilson R; Bossong MG; Appiah-Kusi E; Petros N; Brammer M; Perez J; Allen P; McGuire P; Bhattacharyya S
    Transl Psychiatry; 2019 Aug; 9(1):203. PubMed ID: 31439831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.